Xbrane Biopharma AB (publ) (XBRANE) Earnings Call Transcripts
Xbrane Biopharma AB (publ)'s Latest Earnings Call - Q1 FY2026
In Q1 2026, Xbrane Biopharma AB reported revenue of SEK 17.3 million, primarily from Ximluci sales, with a profit margin of 39%. The company maintained its market share in Europe despite competitive pricing pressures. Management highlighted ongoing cost reduction initiatives expected to impact positively from 2027. The resubmission of the BLA to the FDA for Ximluci marks a critical regulatory step, with a decision anticipated in the second half of 2026. No changes were made to guidance, but the strategic partnership with Intas for Xdivane financing was a notable development.
Reported metrics
| Metric | Value |
|---|---|
| Revenue | SEK 17.3 million (inline) |
| Profit Margin | 39% (inline) |
| Operating Cash Flow | SEK 8.5 million (inline) |
| Cash Balance | SEK 66.7 million (neutral) |
Guidance from management
No changes to guidance were announced. Management is focused on cost reduction and regulatory progress, with expectations for Ximluci FDA approval in the second half of 2026.
What analysts pressed on
Analysts expressed interest in the likelihood of Intas exercising the 40-month profit-sharing option. Management stated it is 'impossible to estimate' due to market uncertainties.
Main topics on the call
- Ximluci Market Performance — Ximluci maintained an 8% market share in Europe despite a competitive pricing environment. Management noted, 'volumes have gone down slightly compared to the last quarter,' but emphasized efforts to 'maintain profit marg...
- Cost Reduction Initiatives — Xbrane is implementing cost reduction measures for Ximluci, aiming for results from 2027 onwards. The focus is on 'reducing production cost' to enhance competitiveness.
- Regulatory Progress for Ximluci — The BLA for Ximluci was resubmitted to the FDA, with expectations for a 6-month review period. Management is hopeful for 'an approval during the second half of this year.'
- Xdivane Development — Xdivane is on track for a regulatory submission in the second half of 2027, with a potential launch in 2029. The partnership with Intas includes financing arrangements for CMC activities.
Read the full Xbrane Biopharma AB (publ) transcript (Q1 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About Xbrane Biopharma AB (publ)
Xbrane Biopharma AB (publ) (XBRANE) is a publicly listed company in the Biotechnology industry, within the Health Care sector. It trades on OM and is based in SE. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 29 calls on record spanning May 13, 2020 to July 17, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 29 Xbrane Biopharma AB (publ) earnings call transcripts on record, spanning May 13, 2020 to July 17, 2026. Based on this history, Xbrane Biopharma AB (publ) reports quarterly. The most recent call on file is dated July 17, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- XBRANE
- Exchange
- OM
- Country
- SE
- Sector
- Health Care
- Industry
- Biotechnology
- Calls on record
- 29
- First call
- May 13, 2020
- Most recent
- July 17, 2026
- Reporting cadence
- quarterly